Mathys & Squire will be at the CIPA Life Sciences Conference 2026 on 19th to 20th November in Brighton, UK.
Partners Anna Gregson and Hazel Ford, Of Counsel Alison Haile, and Managing Associate Tom Bosworth, will be attending the 2026 CIPA Life Sciences Conference.
This event is designed for IP professionals in the pharmaceutical, medical technology and biotechnology sectors. A variety of industry experts will share their insights on the latest issues regarding patent law, regulatory frameworks and IP strategy, drawing on their in-depth understanding of the global life sciences landscape. Some of the topics covered will be the journey through litigation, from pre-litigation to exit strategies, and updates on UK, European and UPC case law.
Anna Gregson is a leading IP strategist, delivering tailored guidance to clients across a wide range of sectors within life sciences & chemistry. She specialises in strategic patent management, including drafting and prosecuting patent applications, coordinating global patent portfolios, due diligence and FTO analysis. With a strong background in biochemistry and biotechnology, her technical expertise enables her to provide specialist IP advice in a wide range of areas, including technologies such as cell and gene therapies, vaccine technologies, antibodies, viruses and virus-like particles, siRNA technology, biomarkers and diagnostics, expression systems, recombinant protein technology and therapeutics.
Hazel Ford has extensive experience drafting and prosecuting patent applications globally with experience of patent prosecution at the EPO. She provides expert advice to clients on all aspects of patent strategy, rooted in her comprehensive knowledge of technologies in the life sciences and the commercial landscape. The areas in which she specialises span biotechnology, including antibodies, vaccines, genes and proteins, and pharmaceuticals, including drug formulation, diagnostics and new administration regimes. In addition, she has substantial experience with EPO opposition and appeal proceedings. She has previously taken part in talks and webinars, offering her valuable insights on the latest developments at the EPO and UC, and how these may impact strategic decision-making.
Alison Haile is experienced in managing and prosecuting large patent portfolios worldwide, and providing full strategic advice and opinions in relation to all patent-related aspects of her clients’ businesses. She also provides specialist guidance on due diligence for high value mergers & acquisitions and licensing agreements, and coordinates the filing and prosecution of SPCs and paediatric extensions Europe-wide. The core of Alison’s practice lies in chemistry and life sciences with a focus on the pharmaceutical and nutritional sectors, particularly in relation to drug formulations, new medical uses, drug combinations, dosage regimes, drug delivery, pharmaceutical chemistry, nutritional supplements, foodstuffs, cosmetic formulations and pharmaceutical patent lifecycle management.
Tom Bosworth handles a mix of EPO prosecution, opposition and appeal work, as well as the global prosecution of patent portfolios. He has extensive experience across a wide range of life science technologies including antibodies, cell and gene therapy, and cancer vaccines, providing strategic guidance to clients from startups to global pharmaceutical companies. He also provides freedom to operate and validity advice.
Please reach out to our team if you are interested in arranging a meeting.
For more information on the event, click here.
Contact our team
Anna Gregson – Partner | [email protected]
Hazel Ford – Partner | [email protected]
Alison Haile – Of Counsel | [email protected]
Tom Bosworth – Managing Associate | [email protected]
